TIAA CREF Investment Management LLC decreased its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 6.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,814 shares of the specialty pharmaceutical company’s stock after selling 8,796 shares during the period. TIAA CREF Investment Management LLC’s holdings in AMAG Pharmaceuticals were worth $2,792,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the company. Advisors Asset Management Inc. raised its stake in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares during the period. Mason Street Advisors LLC raised its stake in AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares during the period. Sei Investments Co. raised its stake in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares during the period. Baird Financial Group Inc. purchased a new stake in AMAG Pharmaceuticals during the first quarter worth $220,000. Finally, Affinity Investment Advisors LLC raised its stake in AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 3,310 shares during the period.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 17.15 on Friday. The stock has a 50 day moving average of $18.88 and a 200-day moving average of $20.58. The stock’s market cap is $605.19 million. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.45 earnings per share. Equities research analysts predict that AMAG Pharmaceuticals, Inc. will post ($1.37) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/tiaa-cref-investment-management-llc-reduces-stake-in-amag-pharmaceuticals-inc-nasdaqamag-updated-updated.html.
A number of analysts recently weighed in on the stock. BidaskClub lowered shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Barclays PLC reaffirmed a “hold” rating and set a $25.00 target price on shares of AMAG Pharmaceuticals in a report on Monday, May 15th. Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th. Finally, Cantor Fitzgerald reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average price target of $28.09.
In other news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is currently owned by insiders.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.